Acute pancreatitis due to intragastric balloon hyperinflation (with video).
Ontology highlight
ABSTRACT:
SUBMITTER: Barrichello S
PROVIDER: S-EPMC8752042 | biostudies-literature | 2020 May
REPOSITORIES: biostudies-literature
Publications
Acute pancreatitis due to intragastric balloon hyperinflation (with video).
Barrichello Sérgio S de Moura Diogo Turiani Hourneaux DTH Hoff Anna Carolina AC Veinert André A Thompson Christopher C CC
Gastrointestinal endoscopy 20191219 5
Similar Datasets
Project description:IntroductionObesity is a complex multifactorial disease that affects populations worldwide. In Kuwait, the prevalence of obesity is a major public health problem. Intra-Gastric Balloon (IGB) is commonly used as a non-operative strategy among bariatric patients. However, with the increasing use of IGB, life-threatening adverse outcomes are widely reported.Presentation of casesA case series five patients presenting with pancreatitis from IGB in Kuwait is reported to better investigate the emerging complications of IGB. Three types of IGB were inserted, these include the Orbera Intragastric Balloon System, Orbera365 Intragastric Balloon System, and the Spatz Adjustable Gastric. The clinical course of balloon pancreatitis is described.DiscussionThe case series examined existing case reports of IGB associated pancreatitis in the literature, in addition to the investigated clinical outcomes. Patients presented with mild pancreatitis, and removal of balloon resulted in significant improvement in symptoms. Pathogenesis of balloon pancreatitis could be secondary to the pancreas compression by the IGB.ConclusionDespite the rarity of balloon pancreatitis, it needs to be recognized as a complication of IGB insertion. Further research is needed to better understand the implications of the balloon size, shape, volume and location of balloon insertion in order to prevent this fatal complication.
| S-EPMC7486575 | biostudies-literature
Project description:BackgroundAcute pancreatitis (AP) is a rare but serious complication of intragastric balloon (IGB) therapy. Despite the popularity of IGBs for weight loss, the incidence and risk factors of AP post-IGB insertion are not well understood. This study aimed to identify potential predictors and risk factors of AP in IGB patients.MethodsA retrospective time-to-event study was conducted over 7 years, encompassing patients who received IGBs between January 2017 and 2024. Cox regression analyses were performed to identify risk factors. The incidence of AP was evaluated as a secondary outcome. Patients were categorized into the AP and non-AP groups at a 1:3 ratio. The Revised Atlanta Classification was used to diagnose AP.ResultsAmong 450 patients with IGB, 25 developed AP, yielding an incidence of 5.56%. The Orbera balloon was associated with a lower AP risk (HR 0.29, 95% CI: 0.09-0.96; P = 0.042). The median time to AP onset was 40 days. Higher preprocedural BMI and age > 30 years showed a trend toward reduced AP risk, though not statistically significant.ConclusionsAP following IGB insertion is uncommon but may be underreported, with substantial variability in onset time. The Orbera balloon demonstrated a protective effect, highlighting the role of balloon type in AP risk. These findings underscore the importance of balloon selection and the need for further prospective studies to confirm these results and optimize AP risk management in IGB patients.
| S-EPMC11836173 | biostudies-literature
Project description: Not available
| S-EPMC1860106 | biostudies-literature
Project description:Superinfected intragastric balloon removal.
| S-EPMC11009539 | biostudies-literature
Project description:Intestinal obstruction resulted from balloon migration is an extremely rare but serious late complication of the intragastric balloon (IGB). The aim of this study is to report a case of small bowel obstruction occurring in a middle age corpulent female following embedding of IGB. A 47-year-old obese female presented with abdominal pain, nausea, and vomiting for two days. She had a history of an endoscopically placed IGB nine months before presentation. Physical examination showed an obese woman with mild distress, and the right upper abdomen was tender. The plain abdominal radiograph showed gas shadow in the stomach and the duodenum, esophago-gastro-duodenoscopy showed an empty stomach and balloon migration from the stomach. Under general anesthesia, laparotomy was performed, a three-centimeter antimesenteric enterotomy was done and the balloon extracted from the proximal jejunum. Intestinal obstruction is an extremely rare complication of IGB. It should be managed by laparotomy and extraction of the balloon.
| S-EPMC6168928 | biostudies-literature
Project description:The placement of an intragastric balloon (IGB) plays an increasingly important role in the treatment of obesity. The authors describe the cases of 2 female patients, 34 and 62 years old, who were submitted to the implantation of a Spatz3® IGB to treat obesity. Ten to fourteen weeks later, the patients presented complaints of epigastric pain, vomiting, and abdominal distension. A bulging of the upper abdominal wall was noticed upon physical examination. Upper gastrointestinal endoscopy confirmed the clinical suspicion of IGB hyperinflation. It was decided to remove the 500 mL of saline solution with methylene blue from inside the balloon. During the same procedure, the IGB was refilled with 500 mL of fresh saline solution, methylene blue, and empiric β-lactam antibiotic. The extracted content of the hyperinflated IGB was sent for microbiological culturing and was found to be positive for Streptococcus viridans in one of the cases. In the other case, the culture examination was negative, and after 8 weeks, the patient presented again with hyperinflation of the IGB. It was then decided to substitute the IGB with another balloon; the procedure was uneventful. The content of the removed IGB was sent for microbiological testing, and colonization by Candida tropicaliswas confirmed. This is a rare but potentially serious complication of IGB placement. Randomized trials are needed to clarify the role of antibiotics and antifungals in primary and secondary prophylaxis against IGB hyperinflation.
| S-EPMC7841804 | biostudies-literature
Project description: Not available
| S-EPMC3153551 | biostudies-literature
Project description:Intragastric balloon (IGB) insertion has been most frequently used in the West as an effective endoscopic treatment for morbid obesity, in practice. Recently, there is a growing number of cases requiring IGB deployment for obesity treatment in Korea. One of the reported complications of IGB use is gastric perforation. A 47-year-old woman was admitted to the hospital with mild symptoms, 7 weeks after having an IGB placed. Esophagogastroduodenoscopy was performed and gastric ulcer perforation was observed in the ulcer base, where food particles were impacted. Laparoscopic primary repair was done successfully. This was a case of gastric perforation, secondary to poor compliance with a proton-pump inhibitor (PPI). PPI and Helicobacter pylori eradication are important for ulcer prevention following IGB deployment.
| S-EPMC5719922 | biostudies-literature
Project description:Video Video 1 Video of EGD showing deflation of balloon and removal.
| S-EPMC10422079 | biostudies-literature
Project description:Background/aimIntragastric balloon (IGB) is an effective and safe method of weight reduction. However, IGBs have been associated with a high rate of weight regain post removal. Accordingly, ways to improve sustained weight reduction including concomitant treatment with Glucagon-like peptide 1 (GLP-1) agonists have been proposed. This study aims to evaluate the effect of adding Liraglutide to IGB insertion on sustained weight reduction.Patients and methodsA retrospective analysis of all cases treated with IGB with or without Liraglutide was performed. Outcomes were statistically compared.ResultsA total of 108 patients were included; 64 were treated with IGB alone and 44 with IGB + Liraglutide. Six months after removing IGB, patients treated with IGB + Liraglutide had a higher mean weight loss post treatment completion (10.2 ± 6.7 vs. 18.5 ± 7.6, P = <0.0001) than those treated with IGB alone. After adjusting for covariates, patients treated with IGB alone demonstrated a higher mean body weight loss at the time of IGB removal (coefficient 7.71, 95% CI = 4.78-10.63), and a higher odds of treatment success 6 months post IGB removal (OR = 5.74, 95% CI = 1.79-188.42). Baseline body mass index appeared to be a significant predictor of mean body weight loss at the time of balloon removal.ConclusionsAdding Liraglutide to IGB does not appear to decrease the risk of weight regain 6 months post IGB removal.
| S-EPMC5385714 | biostudies-literature